Michael G. King, Jr.
Michael G. King, Jr. serves as our EVP & Chief Financial Officer, joining SAB in October 2023. Prior to joining SAB Biotherapeutics, Michael King was an award-winning equity research analyst covering the biotechnology sector. He also has several years’ experience in the biotech industry. Prior to joining SAB, Mr. King was a Managing Director and Co-Head of Healthcare Research at EF Hutton Group, where he served as a Senior Biotechnology Analyst. Prior to his role at Hutton, he served as Managing Director and Senior Biotechnology Analyst at HC Wainwright. Mr. King joined Wainwright after his role as Entrepreneur in Residence at Fortress Biotech (FBIO), a New York City-based specialty company that creates start-ups. Prior to FBIO, he spent over five years as Managing Director and Senior Biotechnology Analyst at JMP Securities. He was previously a Managing Director and senior research analyst at Rodman & Renshaw, a Senior Vice President and Director of Corporate Development at publicly traded ZIOPHARM Oncology, and a Managing Director and senior equity analyst at Wedbush Securities. Beforehand, he served as a Managing Director and senior biotechnology analyst both at Merriman Curhan Ford and at Rodman & Renshaw, where, in his initial tenure with the company, he was also the Director of Research. Additionally, Mr. King has held senior equity research positions at Banc of America Securities, Robertson Stephens, Vector Securities and Dillon Read & Co., covering a wide range of market capitalizations and therapeutic categories. He began his career as a biotechnology specialist in the private client sales divisions of Alex. Brown & Co., Hambrecht & Quist and Kidder, Peabody & Co. In 2013, Mr. King ranked first among all stock pickers in the pharmaceuticals category in the annual “Best on the Street” analyst survey conducted by The Wall Street Journal. Mr. King holds a BA in finance from The Bernard M. Baruch College of the City University of New York.